Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

Inclusion Criteria:

All Individuals:

- Be a nonsmoker or consume < 20 cigarettes per day

- Have a calculated body mass index (BMI) from 18 to 36 kg/m^2, inclusive, at study
screening

- Have either a normal 12-lead electrocardiogram (ECG) or one with abnormalities that
are considered clinically insignificant by the investigator

- Screening labs within defined thresholds

Individuals with mild, moderate, or severe renal impairment must also meet the following
additional inclusion criteria to be eligible for participation in this study:

- Must have diagnosis of chronic (> 6 months), stable renal impairment with no
clinically significant changes within 3 months (90 days) prior to study drug
administration (Day 1)

- Individuals with severe renal impairment, creatinine clearance (CLcr) must be 15-29
mL/min, inclusive (using the Cockcroft-Gault method) based on serum creatinine and
actual body weight as measured at the screening evaluation. If an individual's score
changes during the course of the study, the score at screening will be used for
classification.

- Individuals with moderate renal impairment, CLcr must be 30-59 mL/min, inclusive
(using the Cockcroft-Gault method) based on serum creatinine and actual body weight
as measured at the screening evaluation. If an individual's score changes during the
course of the study, the score at screening will be used for classification.

- Individuals with mild renal impairment , CLcr must be 60-89, inclusive mL/min (using
the Cockcroft-Gault method) based on serum creatinine and actual body weight as
measured at the screening evaluation. If an individual's score changes during the
course of the study, the score at screening will be used for classification.

Individuals with normal renal function must also meet the following additional inclusion
criteria to be eligible for participation in this study:

- Must, in the opinion of the Investigator, be in good health based upon medical
history, physical examination, vital signs, and screening laboratory evaluations

- Must have an CLcr of ≥ 90 mL/min (using the Cockcroft-Gault method) based on serum
creatinine and actual body weight as measured at the screening evaluation.

Exclusion Criteria:

- History of meningitis or encephalitis, epilepsy, seizures, migraines, tremors,
myoclonic jerks, narcolepsy, obstructive sleep apnea, anxiety, syncope, head injuries
or a family history of seizures

- Presence or history of cardiovascular disease (including history of myocardial
infarction based on ECG and/or clinical history, any history of ventricular
tachycardia, congestive heart failure, cardiomyopathy, or left ventricular ejection
fraction < 40%), cardiac conduction abnormalities, a family history of Long QT
Syndrome, or unexplained death in an otherwise healthy individual between the ages of
1 and 30 years

- Syncope, palpitations, or unexplained dizziness

- Implanted defibrillator or pacemaker

- Medical history of renal carcinoma or hepatorenal syndrome.

- Individuals receiving or anticipating use of hemodialysis, peritoneal dialysis, or
any other renal replacement therapy or other medical procedure that serves as a
surrogate for renal function during the study.

- Individuals with fluctuating or rapidly deteriorating renal function. Assessment of
the stability of the individual's renal function will be determined by the
investigator.

- Renal allograft recipients

- Experienced hypertensive crisis, required the addition of ≥1 antihypertensive drug,
or required more intensive antihypertensive therapy (eg, addition of a new drug
class) in the last 3 months